Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Daniel M. F. Claassens, Pim W. M. van Dorst, Gerrit J. A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W. J. van 't Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M. Tjon Joe Gin, Folkert W. Asselbergs, Arend Mosterd, Jean-Paul R. Herrman, Willem J. M. Dewilde, Maarten J. Postma, Vera H. M. Deneer, Jurriën M. ten Berg*, Cornelis Boersma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Downloads (Pure)

Abstract

INTRODUCTION: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary percutaneous coronary intervention (PCI).

OBJECTIVE: In this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel.

METHODS: A 1-year decision tree based on the POPular Genetics trial in combination with a lifelong Markov model was developed to compare costs and quality-adjusted life-years (QALYs) between a genotype-guided and a standard P2Y12 inhibitor strategy in patients with myocardial infarction undergoing primary PCI. The cost-effectiveness analysis was conducted from a Dutch healthcare system perspective. Within-trial survival and utility data were combined with lifetime projections to evaluate lifetime cost effectiveness for a cohort of 1000 patients. Costs and utilities were discounted at 4 and 1.5%, respectively, according to Dutch guidelines for health economic studies. Besides deterministic and probabilistic sensitivity analyses, several scenario analyses were also conducted (different time horizons, different discount rates, equal prices for P2Y12 inhibitors, and equal distribution of thrombotic events between the two strategies).

RESULTS: Base-case analysis with a hypothetical cohort of 1000 subjects demonstrated 8.98 QALYs gained and €725,550.69 in cost savings for the genotype-guided strategy (dominant). The deterministic and probabilistic sensitivity analysis confirmed the robustness of the model and the cost-effectiveness results. In scenario analyses, the genotype-guided strategy remained dominant.

CONCLUSION: In patients undergoing primary PCI, a CYP2C19 genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel resulted in QALYs gained and cost savings.

TRIAL REGISTRATION: Clinicaltrials.gov number: NCT01761786, Netherlands trial register number: NL2872.

Original languageEnglish
Pages (from-to)195-206
Number of pages12
JournalAmerican journal of cardiovascular drugs
Volume22
Issue number2
Early online date7-Sep-2021
DOIs
Publication statusPublished - Mar-2022

Keywords

  • ACUTE CORONARY SYNDROME
  • ST-SEGMENT ELEVATION
  • ANTIPLATELET THERAPY
  • TASK-FORCE
  • AMERICAN-COLLEGE
  • CLOPIDOGREL
  • TICAGRELOR
  • GUIDELINES
  • PRASUGREL
  • SELECTION

Cite this